MD Conference Express AHA 2013 - (Page 6)

Dear Colleagues, We are delighted to share with you the official peer-reviewed highlights from the American Heart Association Scientific Sessions 2013 held in Dallas in November. The scope and quality of the abstracts presented continue to make Scientific Sessions an exciting and innovative forum where advances in research can be translated into practical applications for the clinician. The articles selected for this issue of MD Conference Express®, the official highlights report for Scientific Sessions 2013, represent the most newsworthy and cutting edge items of relevance to a broad array of practitioners. Some of the studies presented live at Scientific Sessions 2013 and in the pages of MD Conference Express will influence clinical practice and will allow us to better understand how to manage important conditions and how to devise even new therapies. The ENGAGE AF-TIMI 48 trial, the largest-ever clinical trial of a novel anticoagulant, compared two once-daily dose regimens of the oral factor Xa inhibitor to well-managed warfarin in patients with atrial fibrillation. Both regimens were noninferior to warfarin for stroke prevention, reduced bleeding, and lowered cardiovascular death. The TOPCAT trial evaluated spironolactone in patients with heart failure and preserved ejection fraction, and failed to show a benefit for the clinical composite primary endpoint, although patients randomized to spironolactone did have significantly fewer hospitalizations for heart failure Renal artery stenting failed to offer incremental benefit over medical management for patients with renal artery stenosis and hypertension or chronic kidney disease in the CORAL trial. Results from the ERASE trial found that endovascular revascularization plus supervised exercise therapy lead to greater 1-year improvements in quality of life and pain-free and maximum walking distance compared with exercise alone. In addition to learning about the results of top late-breaking clinical trials in this dedicated highlights report, you will also find new information in selected, challenging areas of cardiovascular medicine, the roles of anticoagulants, devices, and antidotes for stroke prevention in atrial fibrillation; managing patients with heart failure and diabetes; and cardiovascular disease as a result of cancer treatment. We hope that you find the articles and practical perspectives that are contained in the pages of this issue of MD Conference Express helpful in integrating this new information into your clinical practice. For more information, please visit www.mdconferencexpress.com. Robert P. Giugliano, MD, SM Associate Physician Cardiovascular Division Brigham and Women's Hospital Associate Professor in Medicine Harvard Medical School Boston, MA Jacob A. Udell, MD, MPH Associate Physician University of Toronto Toronto, Ontario, Canada Nihar R. Desai, MD, MPH Associate Physician Cardiovascular Division Yale-New Haven Hospital New Haven, CT 6 Marc P. Bonaca, MD, MPH Associate Physician Cardiovascular Division Brigham and Women's Hospital Instructor in Medicine Harvard Medical School Boston, MA Matthew Cavender, MD Cardiovascular Fellow Cardiovascular Division Brigham and Women's Hospital Boston, MA Dylan L. Steen, MD Cardiovascular Fellow Cardiovascular Division Brigham and Women's Hospital Boston, MA December 2013 www.mdconferencexpress.com  http://www.mdconferencexpress.com http://www.mdconferencexpress.com

Table of Contents for the Digital Edition of MD Conference Express AHA 2013

Contents

MD Conference Express AHA 2013

https://www.nxtbook.com/nxtbooks/md_conference_express/AHA2013
https://www.nxtbookmedia.com